Cited by 322Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 35 of the 38 references it cites were found in a registry or an index.

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Open access

Zhou, Caicun, Wu, Lin, Fan, Yun, Wang, Zhehai, Liu, Lianke, Chen, Gongyan, Zhang, Li, Huang, Dingzhi, Cang, Shundong, Yang, Zhixiong, Zhou, Jianying, Zhou, Chengzhi, Li, Baolan, Li, Juan, Fan, Min, Cui, Jiuwei, Li, Yuping, Zhao, Hui, Fang, Jian, Xue, Jianxin, Hu, Chengping, Sun, Ping, Du, Yingying, Zhou, Hui, Wang, Shuyan, Zhang, Wen·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2021.04.011

Open this paper in CoChat — free account Open PDF

Abstract

Introduction The standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum plus gemcitabine. Sintilimab, an anti-programmed cell death protein 1 antibody, plus platinum and gemcitabine (GP) has revealed encouraging efficacy as first-line therapy for sqNSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with GP.Methods ORIENT-12, a randomized, double-blind, phase 3 study, was conducted at 42 centers in the People's Republic of China (ClinicalTrials.gov, number NCT03629925). Patients with locally advanced or metastatic sqNSCLC and without EGFR-sensitive mutations or ALK rearrangements were enrolled in the study. The stratification factors included clinical stage, choice of platinum, and programmed death-ligand 1 tumor proportion score. The patients, investigators, research staff, and sponsor team were masked to treatment assignment. Eligible patients were randomized 1:1, using an integrated web-response system, to receive sintilimab 200 mg or placebo plus GP every 3 weeks for four or six cycles, followed by sintilimab or placebo as maintenance therapy until disease progression or 2 years. The primary end point was progression-free survival (PFS), assessed by an independent radiographic review committee.Results Between September 25, 2018 and July 26, 2019, a total of 543 patients were screened, of whom 357 patients were randomized to the sintilimab-GP group (n = 179) and the placebo-GP group (n = 178). After a median follow-up period of 12.9 months, sintilimab-GP continued to reveal a meaningful improvement in PFS than placebo-GP (hazard ratio = 0.536 [95% confidence interval: 0.422-0.681], p < 0.00001). Treatment-emergent adverse events of grade 3 or worse occurred in 86.6% patients in the sintilimab-GP group and in 83.1% in the placebo-GP group. The incidence of treatment-emergent adverse event leading to death was 4.5% and 6.7% in the two treatment groups, respectively.Conclusions Regarding PFS, sintilimab plus GP reveals clinical benefit than GP alone as first-line therapy in patients with locally advanced or metastatic sqNSCLC. The toxicity was acceptable, and no new unexpected safety signals were observed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.04.011

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203

Show all 38 references

Sorted by citations

Items 201–300 of 322

Remarkable response to PD-1 inhibitor in a patient with extensive-stage small cell lung cancer: a case report and literature review
Yuan, G., Liu, X., Zhang, X., Song, W., Lu, J., Ding, Z., & Chen, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267606 · Cited by 3
NeoSCORE II: Three Vs Four Cycles of Neoadjuvant Sintilimab + Chemotherapy for Squamous Non-Small-Cell Lung Cancer
Zhang, X., Shao, M., Yao, J., Zhao, L., Li, L., Chen, M., Zhang, Y., Liu, H., Chen, Z., Li, B., et al. (2024) · Future Oncology · doi:10.2217/fon-2024-0026 · Cited by 4
Self-citation
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
Xiang, H., Meng, K., Wu, M.-Y., & Tan, C. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2379600 · Cited by 3
Sintilimab Combined with Nanoparticle Albumin-Bound Paclitaxel-Based Chemotherapy in Severe Locally Advanced or Metastatic Squamous NSCLC Showed Good Efficacy and Safety: A Pilot Retrospective Analysis
Zhong, Y., Mao, Y., Fu, X., & Huang, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s484765 · Cited by 3
Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis
Xia, Z., Hong, J., Yu, X.-Y., Ran, Y.-H., Xie, H.-L., Zhou, Z., Zuo, J., Chen, T., Meng, J., & Yang, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1422039 · Cited by 2
An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor
Shi, X., Chen, L., Lou, L., He, Q., Lou, G., Hong, W., Shao, L., Zhao, J., Gu, C., Yu, X., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71191 · Cited by 3
Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors
Reguart, N., & Reyes, R. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.001 · Cited by 3
Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
Wang, J., Xiao, X., Dong, X., Wu, G., Wang, X., & Zhang, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931074 · Cited by 3
First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials
Chen, W., Liu, H., Li, Y. H., Xue, W., Fan, S., Sun, J., Liu, S., Liu, Y., & Zhang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1365255 · Cited by 2
Self-citation
Research Progress of SBRT Combined With Immunotherapy in Locally Advanced Head and Neck Cancer
Feng, Y.-M., Zhou, P., Duan, X., Ye, Q., & Xie, K. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001204 · Cited by 2
The efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in advanced or metastatic gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
Piao, H., Li, W., Chengde, L., Li, H., Xiaohan, Z., Liu, Y., Xuezheng, Z., & Mao, S. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03861-3 · Cited by 2
Tertiary Lymphoid Structures Predict Prognosis and Immune Checkpoint Inhibitor Efficacy in Lung Squamous Cell Carcinoma
Chen, K., Zhou, S., Zhou, P., Sun, Z., Xu, Y., Chen, Z., Zhang, L., Pi, W., Gan, M., & Yang, H. (2025) · Immunology · doi:10.1111/imm.70027 · Cited by 2
Self-citation
SOX2 transactivates NRF2 to promote carboplatin resistance in lung squamous cell carcinoma
Gao, H., Li, C., Sun, J., Deng, L., Li, J., Wu, Z., & Chen, H. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025228 · Cited by 2
Self-citation
A Retrospective Study of First‐Line Immunotherapy for Advanced Non‐Small Cell Lung Cancer in the Elderly
Yang, S., Zhu, Y., Liu, S., & Xiao, K. (2025) · Aging Medicine · doi:10.1002/agm2.70052 · Cited by 2
Efficacy of first-line immune checkpoint inhibitors in advanced non-small-cell lung cancer with or without brain metastases: a systematic review and network meta-analysis
Luo, J., Han, M., Sima, M., Cui, Y., Yu, Z., Dong, C., Ma, K., & Yue, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1809450 · Cited by 2
Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers
Mohanty, S. K., Mishra, S. K., Amin, M. B., Agaimy, A., & Fuchs, F. S. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000395 · Cited by 3
Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study
Yang, B. Y., Li, Y., Deng, J., Yang, H. J., & Sun, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210267 · Cited by 2
Self-citation
The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis
Chen, B., Xu, A., He, Y., Zhang, Y., Cheng, D., Fang, Y., Ruan, J., Dai, M., Wang, Y., & Zhang, J. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08344-2 · Cited by 2
Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy
Zhu, Z., Bao, X., Shi, H.-Y., & Gu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1283008 · Cited by 2
A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience
Yao, D., Zhu, X., Guo, J., Dong, X., Zeng, Y., Fu, X., & Yu, W. J. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100787 · Cited by 2
A case report of cStage IIIB squamous cell lung carcinoma completely resected after downstaging with neoadjuvant therapy
Li, J., Zu, P., Jakopović, M., Legras, A., Saji, H., Onodera, K., Schlachtenberger, G., & Liu, H. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-522 · Cited by 2
Self-citation
Reversible elevation of creatine kinase and creatinine caused by sintilimab-induced hypothyroidism: A case report
Liu, S., Zhao, Z.-G., Zhai, R.-R., Wang, L.-J., Yang, C., Ma, Q.-B., & Wang, L. (2024) · Medicine · doi:10.1097/md.0000000000040080 · Cited by 2
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China
Wang, L., Lv, N., Gao, Y., Yan, C., Huo, X., & Diao, R. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-091650 · Cited by 2
Efficacy and safety of immunotherapy in real-world patients with advanced non-small cell lung cancer
Yin, N., Yang, R., Liu, X., & Chen, X. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100908 · Cited by 2
Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies
Shan, B., Li, M., Yang, R., Wang, G., Hou, J., & Wen, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1632740 · Cited by 2
The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients
Wu, B., Sun, C. M., Sun, X., & Li, X. (2023) · Medicine · doi:10.1097/md.0000000000034849 · Cited by 2
Chemical-induced lung tumor in Tg-rasH2 mice: a novel mouse tumor model to assess immune checkpoint inhibitors combined with a chemotherapy drug
Hagiwara, T., Numano, T., Hara, T., Sugiyama, T., Mera, Y., Tamano, S., & Miyata, H. (2022) · Journal of Toxicologic Pathology · doi:10.1293/tox.2022-0040 · Cited by 1
Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer
Zhang, J., Lv, P.-Y., Zhao, X. Q., Liu, M., Qiu, L.-P., Yang, Z.-Z., Sun, S., & Zhang, G. (2024) · BMC Cancer · doi:10.1186/s12885-024-12708-6 · Cited by 1
Self-citation
Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer
Jiang, T., Chen, J., Wang, H., Wu, F., Chen, X., Su, C., Zhang, H., Zhou, F., Yang, Y., Zhang, J., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003094 · Cited by 1
Self-citation
Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study
Sun, L., Tian, Y., Zhang, S., Huang, L., Ma, J., & Han, C. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100780 · Cited by 1
Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review
Zhao, X., Wang, X., Liu, S., Cheng, P., Chen, J., & Liu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548452 · Cited by 1
Meta-Analysis of the Efficacy and Safety of Sintilimab in Combination With Chemotherapy for Advanced Non–Small-Cell Lung Cancer
Pan, L., Chen, Q., Liang, N., Liang, J., & Guo, Y. (2025) · Current Therapeutic Research · doi:10.1016/j.curtheres.2025.100796 · Cited by 1
Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study
Xu, J., Meng, M., He, S., Wang, S., Peng, J., Yao, B., Li, Y., Hu, Y., Qian, X., Wang, T., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251345913 · Cited by 1
Self-citation
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials
Zhang, J.-F., Liu, M., Li, D., Luo, J., & Wang, M. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03934-8 · Cited by 1
Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves
Ma, J.-T., Yang, M., Zhang, S., Huang, L., Sun, L., & Han, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104831 · Cited by 2
Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer
Choudhary, F., Safdar, A., Abdin, M. Z., & Farooqi, H. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575415429251007093531 · Cited by 1
First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs
Mao, Z., Zhang, Z., Song, M., He, J., Zheng, J., & Liu, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1709348 · Cited by 1
A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study
Wang, D., Mu, S., Zhang, M., Tao, G., Wang, S., Shen, Y., Xiao, G., Zhang, X., Han, B., Cheng, L., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108881 · Cited by 1
Self-citation
Real-world efficacy assessment for sintilimab in recurrent or metastatic cervical cancer
Zhou, D., Wang, R. W., Huang, L., Yan, P., Ling, K., & Liang, Z. (2025) · PeerJ · doi:10.7717/peerj.20477 · Cited by 1
Case Report of Acute Central Airway Obstruction Induced by Anti‐ PD ‐1 Sintilimab: Clinical Presentation and Review
Ouyang, T., Wang, Z. P., Zhang, W., & Liu, W. (2026) · Clinical Case Reports · doi:10.1002/ccr3.71811 · Cited by 1
Self-citation
Efficacy and safety of SMET12 in combination with toripalimab and chemotherapy in advanced non-small-cell lung cancer patients tested positive for EGFR protein who are treatment-naïve or harbor acquired resistance to standard therapy: a phase 2, multi-cohort clinical trial
Lin, J., Chen, S., Li, M., Weng, L., Xu, H., Wang, Q., Zhang, J., Lin, D., Wang, H., Liu, Q., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1706961 · Cited by 1
Efficacy and safety comparisons of PD-1 versus PD-L1 inhibitors in patients with solid cancer: a systematic review and meta-analysis
Yu, J., Zhou, Q., Wang, G., Shi, S., Wang, H., Yang, J., Sun, X., Li, J., Shi, Y., Wang, J., et al. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.01.004 · Cited by 1
Self-citation
Durable progression-free survival with first-line sintilimab plus chemotherapy followed by sintilimab maintenance in PD-L1-high recurrent cervical cancer: a case report
Liu, J., & Ren, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1736364 · Cited by 1
TRIM29 suppresses malignant progression in lung squamous cell carcinoma by shaping an immunosuppressive tumor microenvironment
Zhou, X., Jia, W., Jiang, H., Zhong, H., Sun, J., Ma, R., Wu, Z., Lin, Z., Lu, L., & Chen, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-48026-z · Cited by 1
Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis
Li, S., He, T., Chen, J., Liu, T. F., Zhao, X., & Dang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1850384 · Cited by 1
Integrated metabolomics and machine learning identify predictive biomarkers via SHAP analysis for sintilimab-induced rash in lung cancer patients
Tian, W., Tang, H., Liu, X., Lv, J., Xu, Y., 华愉教, Xie, F., & Ding, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1846667 · Cited by 1
Efficacy of tislelizumab combined with gemcitabine and resulting changes in CT imaging for advanced non-small cell lung cancer
Li, Z. J., Pu, M., Huang, R., Zhou, P., Zhang, T. H., & Zhang, Y. (2026) · International Journal of Radiation Research · doi:10.66224/ijrr.24.1.9 · Cited by 1
Efficacy of first-line treatment in driver gene-negative non-small cell lung cancer with liver metastases: a Bayesian network meta-analysis
Wu, W., Guo, X., Dong, X., Liang, H., & Zhang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1791664 · Cited by 1
Self-citation
Case report: Rare isolated cystic hepatic metastasis of a patient with squamous cell lung carcinoma history and the prognosis
Liu, C., Chen, X., Su, H., Xia, L., & Lu, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.986603 · Cited by 1
800 Clinicopathological and molecular predictive factors of survival in non-small cell lung cancer patients treated with first-line immunotherapy with or without chemotherapy: a systematic review and meta-analysis
Federico, A. D., Gelsomino, F., Giglio, A. D., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0800 · Cited by 1
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
Andric, Z. G., Gálffy, G., Cobo, M., Szima, B., Stojanović, G. M., Petrovic, M. D., Felip, E., Baz, D. V., Ponce-Aix, S., Juan, Ó., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100461 · Cited by 1
Efficacy and Safety of Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People’s Republic of China: a Systematic Review and Meta-Analysis
Chen, Q., Ma, K., Zhang, L., Lin, W., Wu, X., & Gao, Y. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100678 · Cited by 1
Self-citation
Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression
Bao, H., Zhang, J., Wang, Y., Chen, Z., Luo, X., Li, T., Su, H., Bao, H., Cao, X., & Lin, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1448291 · Cited by 1
Sintilimab Plus Autologous NK Cells as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer Previous Treated with Platinum-Containing ChemotherapyPreprint
Cui, J., Jia, L., Chen, N., Chen, X., Niu, C. S., Liu, Z., Ma, K., Wang, N., Yang, L., Zhao, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4116417 · Cited by 1
Self-citation
Winds From the ORIENT: New Data to Inform RATIONAL Choice?
Bironzo, P., Passiglia, F., & Novello, S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.003
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisPreprint
Chen, C.-Y., Huang, C., Chen, W., Huang, M., & Wei, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-1168265/v1
Response to immune checkpoint inhibitor combined therapies in metastatic BRAF mutant lung cancersPreprint
Yan, N., Zhang, Z., Guo, S., Huang, S., Shen, S., Xu, L., Zhang, H., & Li, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1551063/v1
Cost-effectiveness analysis of sintilimab plus chemotherapy versus chemotherapy alone for the first-line treatment of advanced oesophageal squamous cell carcinomaPreprint
Qi, R., Nie, X., Gao, S., & Liu, G. (2022) · Research Square · doi:10.21203/rs.3.rs-2096333/v1
Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges
Hosseini, M., & Rezaei, N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_52
Clinical Research Progress of Carrilizumab in Patients with Lung Cancer
成, 伟. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121756
Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article)
Sridhar, A., Singh, P. K., & Parikh, K. (2023) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.72631
Research Status and Prospect of Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer
于, 楠. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381762
Progress of Immune Checkpoint Inhibitors as First-Line Monotherapy and Combined Chemotherapy for Advanced Non-Small Cell Lung Cancer with Negative Driver Genes
张, 学. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381815
First-line therapy
Gauthier, M.-P., & Leighl, N. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-69573-2.00017-6
First-Line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer: PD-(L)1 Inhibitors Plus Solvent-Based or Albumin-Bound PaclitaxelPreprint
Huang, J., Li, X., Wang, X., Liu, X., Chen, P., Quan, Q., & Liu, S. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4593225
Current Status and Therapeutic Prospects of Combining Radiotherapy and Immunotherapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
伍, 敏. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13122714
First-line treatment for patients with advanced squamous non-small cell lung cancer: PD-(L)1 inhibitors plus solvent-based or albumin-bound paclitaxelPreprint
Wang, X., Liu, S., Li, X., Liu, X., Chen, P., Quan, Q., & Huang, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3932833/v1
Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Wan, N., Chen, Y., Lu, L., Wang, B., He, L., Liang, H., Xie, F., Jian, X., Ji, B., & Zhang, J. (2024) · European Journal of Cancer Care · doi:10.1155/2024/6004679
Systematic Evaluation of Cost-Utility Analysis of Immunotherapy Combined with Chemotherapy for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer
李, 雪. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143771
Significance of Immune Checkpoints in Lung Cancer
Dimou, A., & Leventakos, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_9
A meta-analysis of the effectiveness and safety of Sintilimab combined with chemotherapy in the trea tment of advanced non-small cell lung cancerPreprint
Pan, L., Chen, Q., Liang, N., Guo, Y., & Guo, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4587063/v1
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS
Pang, J., Zhang, Y., Wang, X., Wu, W., Wan, C., Li, Z., & Du, Y. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108001
Self-citation
New Insights on Success and Failed Drugs
Sun, Z., & Zhou, Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-7274-2_10
Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective
Yu, C., Wu, Y., Geng, Y., Yan, H. M., Zhu, P., Peng, J., Wu, F., Ning, L., Feng, Y., & Shen, A. (2025) · Health Economics Review · doi:10.1186/s13561-024-00588-2
Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study
Huang, Y., Ding, P., Zhang, R., Zhang, Y., Tong, F., Cheng, S., Peng, L., Jie, X., Wang, J., Liu, P., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.02.007
Research Progress of Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
丽, 梅. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153732
Efficacy of immunotherapy remained in patients with recurrent/metastatic non‐small‐cell lung cancer after surgery with or without postoperative thoracic radiotherapy: a bi‐center retrospective study
Wu, Y., Li, R., Tan, F., Cao, J., & Bi, N. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.15384
Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study
Du, Z., Ge, X., Yao, L., Qin, Y., Fan, H., Lv, Y., Du, X., & Liu, Z. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf045
A Case of Combined Traditional Chinese Medicine and Western Medicine in the Treatment of Poorly Differentiated Non-Small Cell Lung Cancer
黎, 扬. (2025) · Traditional Chinese Medicine · doi:10.12677/tcm.2025.144224
Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations
Guo, X., Zhang, H., Shi, Y., He, Q., Liu, A., Zeng, Z., Wang, J., Song, W., Zhang, T., Ding, C., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-271
Self-citation
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studyPreprint
Fu, M., Qu, J., Zhou, J., & Zhou, J. (2025) · Research Square · doi:10.21203/rs.3.rs-7161891/v1
Self-citation
Comprehensive non-small cell lung cancer targets: From computational prediction to clinical breakthroughs in overcoming drug resistance
Zheng, W., He, Z., Liu, J., Zhang, Y., Gong, C., Wang, B., Shen, J., Guo, L., & Liang, T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117333 · Cited by 1
Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 <1% metastatic non-small-cell lung cancer – implications for daily clinical practice
Bryl, M., Stencel, K. M., Knetki‐Wróblewska, M., & Krzakowski, M. J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2557610
Current landscape of cross-line immune checkpoint blockade for cancer treatment
Fan, P., Wu, K., Zhu, C., & Guan, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218135
Sintilimab Pharmacovigilance in Real-World Practice: Analysis Utilizing the WHO VigiAccess DatabasePreprint
Guo, Y., Wen, L., Jiang, F., Pan, L., He, L., Liu, Z., Wu, Q., Lai, Z., Huang, Q., & Li, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7907424/v1
Self-citation
Systematic review and meta analysis of efficacy and safety of immunotherapy plus chemotherapy versus chemotherapy in non small cell lung cancer without EGFR or ALK alterations
Abdelazim, K., Amralla, M. T., Aboismael, A. A., Ghaffar, S. A., Elbehiry, A. I., & Badr, N. H. (2025) · Discover Medicine · doi:10.1007/s44337-025-00514-3
Additional file 1 of Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach
Hui, W., Song, R., Tao, H., Gao, Z., Zhu, M., Zhang, M., Wu, H., Gong, D., Zhang, X., & Cai, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22826938
Additional file 2 of Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study
Wei, Q., Deng, T., Wu, J., Zeng, H., Qi, C., Tan, S., Zhang, Y., Huang, Q., Pu, X., Xu, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25506741
Self-citation
Additional file 1 of Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Zhang, Y., Song, L., Zeng, L., Xiong, Y., Liu, L., Zhou, C., Yang, H., Wang, Z., Xia, Q., Jiang, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20962512
Self-citation
Additional file 1 of Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials
Wang, K., Fu, Z., Sun, G., Ran, Y., Lv, N., Wang, E., & Ding, H. (2024) · Figshare · doi:10.6084/m9.figshare.26740343
Additional file 2 of Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials
Wang, K., Fu, Z., Sun, G., Ran, Y., Lv, N., Wang, E., & Ding, H. (2024) · Figshare · doi:10.6084/m9.figshare.26740346
Additional file 1 of Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study
Wei, Q., Deng, T., Wu, J., Zeng, H., Qi, C., Tan, S., Zhang, Y., Huang, Q., Pu, X., Xu, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25506638
Self-citation
Additional file 1 of Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
Cheng, M., Shao, Y., Li, L., Jiang, M., & Song, Z. (2024) · Figshare · doi:10.6084/m9.figshare.25357778
Additional file 1 of Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study
Zheng, X., Zhang, L., Wu, L., Zhao, J., Sun, J., Fang, Y., Zhou, J., Chu, Q., Shen, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24847153
Self-citation
Anlotinib Plus Sintilimab for BRAF V600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial
Gui, L., Zhu, H., Tang, L. F., Zhu, Y., Zhang, Y., Lu, H., Li, W., Yao, J., Ni, S., Liu, S., et al. (2026) · Thyroid · doi:10.1177/10507256261416838
Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study
Wang, Q., Xiong, A., Mao, C., Wang, W., Cui, J., Fang, J., Zhuang, W., Yang, K., Zuo, W., Yang, J., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04299-x
Self-citation
Isoliquiritigenin combined with gemcitabine inhibited lung cancer by suppressing JAK2/STAT3 signaling via lncRNA-p21/miRNA-4534 axis
Xu, C., Gong, C., Wang, C., Xie, M., Wu, M., Ge, D., Ren, H., Zhang, B., Jiang, Z., & Li, W. (2026) · Journal of Natural Medicines · doi:10.1007/s11418-025-01990-8
Nuclear expression of AIRE in lung squamous cell carcinoma correlates with immune microenvironment remodeling and poor prognosis
Wang, C., Wang, C., Jia, Y., Liu, F., Yuan, X., & Chu, Q. (2026) · Tumori Journal · doi:10.1177/03008916261423494
Chinese Expert Consensus on Immune Checkpoint Inhibitor Therapy for Elderly Patients with Advanced Non‐small Cell Lung Cancer (2025 Edition)
Lin, L., Xin, N., Qian, W., Xu, L., Yumeng, T., Lin, W., Jingyi, W., Zhijie, W., Mingzhao, W., Cao, B., et al. (2026) · Aging Medicine · doi:10.1002/agm2.70067
Immunochemotherapy combined with surgery in oligometastatic non-small cell lung cancer: a retrospective studyPreprint
Li, Z., Mao, Y., Gao, Z., Shao, C., Qiao, W., Duan, H., & Yan, X. (2026) · Research Square · doi:10.21203/rs.3.rs-8684499/v1

Authors: Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., Zhou, J., Zhou, C., Li, B., Li, J., Fan, M., Cui, J., Li, Y., Zhao, H., Fang, J., Xue, J., Hu, C., Sun, P., Du, Y., Zhou, H., Wang, S., & Zhang, W.
Affiliations: First Affiliated Hospital of Guangzhou Medical University (CN)
Hunan Cancer Hospital (CN)
University of Chinese Academy of Sciences (CN)
Shandong Tumor Hospital (CN)
Jiangsu Province Hospital (CN)
Harbin Medical University (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Tianjin Medical University Cancer Institute and Hospital (CN)
Henan Provincial People's Hospital (CN)
Guangdong Medical College (CN)
First Affiliated Hospital Zhejiang University (CN)
Capital Medical University (CN)
Sichuan Cancer Hospital (CN)
Fudan University Shanghai Cancer Center (CN)
First Hospital of Jilin University (CN)
First Affiliated Hospital of Wenzhou Medical University (CN)
Second Affiliated Hospital of Anhui Medical University (CN)
Peking University Cancer Hospital (CN)
Sichuan University (CN)
Xiangya Hospital Central South University (CN)
Yuhuangding Hospital (CN)
First Affiliated Hospital of Anhui Medical University (CN)
Innovent Biologics (China) (CN)
Corresponding author: Zhou, Caicun
ORCID: Zhou, Caicun
Wu, Lin
Fan, Yun
Wang, Zhehai
Zhang, Li
Huang, Dingzhi
Cang, Shundong
Yang, Zhixiong
Zhou, Jianying
Zhou, Chengzhi
Li, Baolan
Li, Juan
Fan, Min
Cui, Jiuwei
Li, Yuping
Zhao, Hui
Fang, Jian
Xue, Jianxin
Hu, Chengping
Sun, Ping
Du, Yingying
Zhou, Hui
Wang, Shuyan
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-09
Volume: 16
Issue: 9
Pages: 1501-1511
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2021.04.011
OpenAlex: W3165007730
Cited by: 322
References: 38
Citations by year: 2026: 42 · 2025: 62 · 2024: 71 · 2023: 70 · 2022: 71 · 2021: 6
FWCI: 19.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: sintilimab, lung squamous cell carcinoma, first-line therapy, immune checkpoint inhibitors, PD-1 inhibitors, progression-free survival, maintenance therapy, treatment-emergent adverse events, EGFR wild-type
MeSH terms: Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Deoxycytidine, Double-Blind Method, Humans, Lung Neoplasms, Platinum, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks